Monte Rosa Therapeutics, Inc.
3.40%
2,236,708
1826457
61225M102
Jan 6, 2026
Jan 9, 2026, 04:19 PM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | Partnership | 3.40% | 2,236,708 | 2,236,708 | 0 |
| Versant Ventures VI GP, L.P. | Partnership | 3.40% | 2,236,708 | 0 | 2,236,708 |
| Versant Ventures VI GP-GP, LLC | Other | 3.40% | 2,236,708 | 0 | 2,236,708 |
| Versant Vantage I, L.P. | Partnership | 1.60% | 1,013,361 | 1,013,361 | 0 |
| Versant Vantage I GP, L.P. | Partnership | 1.60% | 1,013,361 | 0 | 1,013,361 |
| Versant Vantage I GP-GP, LLC | Other | 1.60% | 1,013,361 | 0 | 1,013,361 |
Disclosure Items (2)
Common Stock, par value $0.0001 per share
Monte Rosa Therapeutics, Inc.
321 Harrison Avenue, Boston, MA, 02118
See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
On November 19, 2025, Versant VI sold 15,200 shares of Common Stock at a weighted average price per share of $14.2503 for aggregate proceeds of approximately $216,605.02. On December 4, 2025, Versant VI effected a pro rata distribution without additional consideration of 500,030 shares of Common Stock to its limited partners. On December 16, 2025, Versant VI sold 10,205 shares of Common Stock at a price per share of $17.64 for aggregate proceeds of approximately $180,016.20. On January 7, 2026, Versant VI sold 572,526 shares of Common Stock at a weighted average price per share of $23.3304 for aggregate proceeds of approximately $13,357,260.59. On January 8, 2026, Versant Vantage I effected a pro rata distribution without additional consideration of 560,092 shares of Common Stock to its limited partners.
January 8, 2026